<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01829893</url>
  </required_header>
  <id_info>
    <org_study_id>GP-FITAM-104</org_study_id>
    <nct_id>NCT01829893</nct_id>
  </id_info>
  <brief_title>PK Comparison of GL2701 With Finasteride and Tamsulosin in Combination</brief_title>
  <official_title>Open Label, Randomized Comparative Study to Evaluate the Pharmacokinetic Characteristics Between Coadministered Finasteride Tablet and Tamsulosin HCl Tablet and GL2701 Capsule, in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GL Pharm Tech Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Korea University Anam Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the relative bioavailability and pharmacokinetic characteristics of a newly single&#xD;
      pill combination of finasteride and tamsulosin with a conventional combination of finasteride&#xD;
      and tamsulosin in healthy subjects with a single dose, randomized, open-label, 2-sequence&#xD;
      -2period crossover study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This single dose, open label, balanced, randomized, two-treatment, two-period, two-sequence,&#xD;
      crossover study was conducted to compare the relative bioavailability and pharmacokinetic&#xD;
      characteristics of a newly developed formulation with a conventional formulation in healthy&#xD;
      subjects.&#xD;
&#xD;
      For this, a single-center, randomized, single-dose, open-label, 2-period and 2-sequence&#xD;
      crossover study with a 14-day washout period was conducted in 26 healthy volunteers. Plasma&#xD;
      samples for the analysis of finasteride/tamsulosin were collected up to 48 h after drug&#xD;
      administration. Participants received either reference (in combination of of 0.2mg tamsulosin&#xD;
      and 5mg finasteride) or test drug formulation (single pill combination of 0.2mg tamsulosin&#xD;
      and 5mg finasteride) in the first period and the alternative formulation in the second&#xD;
      period. Plasma concentrations of both tamsulosin and finasteride were determined by validated&#xD;
      high-performance liquid chromatography coupled to tandem mass spectrometry detection.&#xD;
      Pharmacokinetic parameters, including Cmax and AUC, were determined by noncompartmental&#xD;
      analysis. Analysis of variance (ANOVA) was carried out using log-transformed Cmax and AUC,&#xD;
      and the mean ratios and their 90% confidence intervals (CI) were calculated. According to&#xD;
      regulatory requirements set forth by Korea and the US Food and Drug Administration, products&#xD;
      meet the criteria for bioequivalence if the 90% CIs of the mean ratios for Cmax and AUC are&#xD;
      within the range of 0.80 to 1.25.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Finasteride and Tamsulosin pharmacokinetics (Cmax and AUC)</measure>
    <time_frame>48 hr</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Benign Prostatic Hyperplasia (BPH)</condition>
  <arm_group>
    <arm_group_label>Reference arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treated with Reference (in combination of 0.2mg tamsulosin and 5mg finasteride) Intervetion: In combination of 0.2mg finasteride and 5mg tamsulosin simultaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treated with Test formulation (single pill combination of 0.2mg finasteride and 5mg tamsulosin) Intervention : GL2701 capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>In combination of 0.2mg finasteride and 5mg tamsulosin</intervention_name>
    <description>oral medication with 240 mL water</description>
    <arm_group_label>Reference arm</arm_group_label>
    <other_name>GL2701 capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GL2701 capsule</intervention_name>
    <description>oral medication with 240 mL water</description>
    <arm_group_label>Test arm</arm_group_label>
    <other_name>Harunal-D (tamsulosin 0.2mg)</other_name>
    <other_name>Prosca (Finasteride 5 mg)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males age 20 to 45 years&#xD;
&#xD;
          -  Body weight &gt; 50 kg with 18~29 kg/m2 body mass index (BMI)&#xD;
&#xD;
          -  Signed and dated informed consent form which meets all criteria of current FDA and&#xD;
             KFDA regulations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  subjects with acute conditions.&#xD;
&#xD;
          -  presence of history affecting ADME&#xD;
&#xD;
          -  Clinically significant history or current evidence of a hepatic, renal,&#xD;
             gastrointestinal, or hematologic abnormality&#xD;
&#xD;
          -  Hepatitis B, hepatitis C, or HIV infection revealed on the laboratory findings&#xD;
&#xD;
          -  Any other acute or chronic disease&#xD;
&#xD;
          -  A history of hypersensitivity to donepezil&#xD;
&#xD;
          -  A history of alcohol or drug abuse&#xD;
&#xD;
          -  Participation in another clinical trial within 3 months&#xD;
&#xD;
          -  smoked &gt;10 cigarettes daily&#xD;
&#xD;
          -  consumption over 5 glasses daily of beverages containing xanthine derivatives&#xD;
&#xD;
          -  use of any medication having the potential to affect the study results within 10 days&#xD;
             before the start of the study.&#xD;
&#xD;
          -  AST or ALT &gt; 1.25 of upper normal limit&#xD;
&#xD;
          -  total bilirubin &gt; 1.5 of upper normal limit&#xD;
&#xD;
          -  systolic blood pressure &lt; 90 mmHg&#xD;
&#xD;
          -  calculated CLcr using Cockroft-Gault equation &lt; 50 mL/min&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji-Young Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Pharmacology &amp; Toxicology, Anam Hospital, Korea University College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical trial center of Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>April 8, 2013</study_first_submitted>
  <study_first_submitted_qc>April 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2013</study_first_posted>
  <last_update_submitted>April 8, 2013</last_update_submitted>
  <last_update_submitted_qc>April 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Anam Hospital</investigator_affiliation>
    <investigator_full_name>Ji-Young Park</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Benign Prostatic Hyperplasia (BPH)</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>bioequivalence</keyword>
  <keyword>finasteirde</keyword>
  <keyword>tamsulosin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
    <mesh_term>Finasteride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

